Ablynx (ABLYF) Stock Price, News & Analysis

Company Overview

Ablynx was a Belgian biopharmaceutical company focused on discovering and developing medicines based on Nanobodies, small antibody fragments derived from camelid antibodies. Its technology was designed to create therapies with potentially favorable properties, including the ability to bind to difficult or multiple biological targets.

The company developed a pipeline of Nanobody-based treatments for hematology, inflammation, immunology, oncology and other serious diseases. Its most notable product was caplacizumab, marketed as Cablivi, a therapy for acquired thrombotic thrombocytopenic purpura, a rare and potentially life-threatening blood disorder.

Ablynx was founded in 2001 and was headquartered in Ghent, Belgium. The company served international pharmaceutical and biotechnology markets through its own research and development programs and collaborations. Sanofi acquired Ablynx in 2018, after which Ablynx ceased operating as an independent publicly traded company. Edwin Moses served as the company’s chief executive officer during its later independent operations.

Key Stats

• Today's Range: $50.63 to $50.63
• 50-Day Range: $50.63 to $50.63
• 52-Week Range: $12.50 to $55.04
• Volume: N/A
• Average Volume: 5,063 shs
• Market Capitalization: $3.81 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ABLYF
• Previous Symbol: NASDAQ:ABLYF
• CIK: N/A
• Web: www.ablynx.com
• Phone: 329-262-0000
• Fax: N/A
• Employees: N/A
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $62.73 million
• Price / Sales: 60.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 18.68

Miscellaneous

• Outstanding Shares: 75,250,000
• Free Float: N/A
• Market Cap: $3.81 billion
• Optionable: Not Optionable
• Beta: 1.99